Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01TDV
|
|||
| Former ID |
DIB019176
|
|||
| Drug Name |
PMID21742770C1
|
|||
| Synonyms |
GTPL8190; BDBM50400690
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C25H28N6O2
|
|||
| Canonical SMILES |
CN1CCN(CC1)C2=C(C=C(C=C2)NC3=NC4=C(C=C3)C=NN4C5=CC=C(C=C5)OC)OC
|
|||
| InChI |
1S/C25H28N6O2/c1-29-12-14-30(15-13-29)22-10-5-19(16-23(22)33-3)27-24-11-4-18-17-26-31(25(18)28-24)20-6-8-21(32-2)9-7-20/h4-11,16-17H,12-15H2,1-3H3,(H,27,28)
|
|||
| InChIKey |
LZQFMCFJCXQTTG-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aurora B messenger RNA (AURKB mRNA) | Target Info | Inhibitor | [2] |
| Fungal Protein kinase A (Fung ypkA) | Target Info | Inhibitor | [2] | |
| Serine/threonine-protein kinase 33 (STK33) | Target Info | Inhibitor | [1] | |
| Pathway Interaction Database | Aurora B signaling | |||
| Signaling by Aurora kinases | ||||
| Aurora C signaling | ||||
| FOXM1 transcription factor network | ||||
| Aurora A signaling | ||||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||
| Separation of Sister Chromatids | ||||
| Resolution of Sister Chromatid Cohesion | ||||
| RHO GTPases Activate Formins | ||||
| Mitotic Prometaphase | ||||
| WikiPathways | Mitotic Metaphase and Anaphase | |||
| Mitotic Prometaphase | ||||
| Regulation of Microtubule Cytoskeleton | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| APC/C-mediated degradation of cell cycle proteins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res. 2011 Sep 1;71(17):5818-26. | |||
| REF 2 | A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.